Harrow (NASDAQ:HROW) Price Target Raised to $60.00

Harrow (NASDAQ:HROW) had its price target boosted by HC Wainwright from $57.00 to $60.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 145.90% from the company’s previous close.

Separately, B. Riley decreased their price objective on shares of Harrow from $69.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st.

Harrow Trading Up 3.4%

Harrow stock opened at $24.40 on Monday. The stock has a market cap of $895.11 million, a P/E ratio of -25.96 and a beta of 0.41. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. Harrow has a 1 year low of $11.39 and a 1 year high of $59.23. The firm’s 50 day moving average price is $24.79 and its 200-day moving average price is $32.53.

Harrow (NASDAQ:HROW) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.40). The business had revenue of $47.83 million during the quarter, compared to the consensus estimate of $57.00 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. On average, equities analysts predict that Harrow will post -0.53 earnings per share for the current fiscal year.

Institutional Trading of Harrow

A number of hedge funds and other institutional investors have recently modified their holdings of the business. GF Fund Management CO. LTD. purchased a new stake in Harrow during the fourth quarter worth about $25,000. Tower Research Capital LLC TRC boosted its holdings in Harrow by 769.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company’s stock valued at $55,000 after purchasing an additional 1,462 shares in the last quarter. Aquatic Capital Management LLC purchased a new stake in Harrow in the fourth quarter valued at approximately $78,000. AlphaQuest LLC lifted its stake in Harrow by 452.8% in the fourth quarter. AlphaQuest LLC now owns 3,527 shares of the company’s stock valued at $118,000 after buying an additional 2,889 shares during the last quarter. Finally, GAMMA Investing LLC raised its stake in shares of Harrow by 2,401.2% during the first quarter. GAMMA Investing LLC now owns 6,278 shares of the company’s stock worth $1,670,000 after purchasing an additional 6,027 shares during the last quarter. 72.76% of the stock is owned by institutional investors and hedge funds.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.